Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

"Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents.

Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Baki TT, Little WC.

J Am Coll Cardiol. 2008 Feb 12;51(6):607-14. doi: 10.1016/j.jacc.2007.08.064.

2.

3-year comparison of drug-eluting versus bare-metal stents.

Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC.

JACC Cardiovasc Interv. 2009 Mar;2(3):231-9. doi: 10.1016/j.jcin.2008.12.010.

3.

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators.

JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.

5.

Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings.

Harjai KJ, Orshaw P, Boura J, Sporn D.

Am J Cardiol. 2009 Jun 1;103(11):1537-45. doi: 10.1016/j.amjcard.2009.02.017. Epub 2009 Apr 22.

PMID:
19463512
6.

Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW.

J Am Coll Cardiol. 2014 Feb 4;63(4):299-307. doi: 10.1016/j.jacc.2013.09.061. Epub 2013 Nov 6. Review.

7.

Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction.

Kupferwasser LI, Amorn AM, Kapoor N, Lee MS, Kar S, Cercek B, Dohad S, Mirocha J, Forrester JS, Shah PK, Makkar RR.

Catheter Cardiovasc Interv. 2007 Jul 1;70(1):1-8.

PMID:
17580366
8.

Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.

Hannan EL, Racz M, Walford G, Holmes DR, Jones RH, Sharma S, Katz S, King SB 3rd.

JACC Cardiovasc Interv. 2008 Apr;1(2):129-35. doi: 10.1016/j.jcin.2008.01.006.

9.

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.

Circulation. 2012 Jun 12;125(23):2873-91. doi: 10.1161/CIRCULATIONAHA.112.097014. Epub 2012 May 14.

10.

The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.

Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW; Interventional Cardiologists of the Thoraxcenter.

JACC Cardiovasc Interv. 2010 Oct;3(10):1051-8. doi: 10.1016/j.jcin.2010.08.003.

11.

Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience.

Brodie B, Pokharel Y, Fleishman N, Bensimhon A, Kissling G, Hansen C, Milks S, Cooper M, McAlhany C, Stuckey T.

JACC Cardiovasc Interv. 2011 Jan;4(1):30-8. doi: 10.1016/j.jcin.2010.11.004.

12.

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators.

J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.

13.

Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

Lancet. 2011 Jun 25;377(9784):2193-204. doi: 10.1016/S0140-6736(11)60764-2. Epub 2011 Jun 12.

PMID:
21665265
14.

Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.

Brodie BR, Stuckey T, Downey W, Humphrey A, Bradshaw B, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Smith H, Edmunds J, Varanasi J, Simonton CA; STENT (Strategic Transcatheter Evaluation of New Therapies) Group.

JACC Cardiovasc Interv. 2008 Aug;1(4):405-14. doi: 10.1016/j.jcin.2008.06.005. Erratum in: JACC Cardiovasc Interv. 2008 Oct;1(5):601.

16.

Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW.

J Am Coll Cardiol. 2013 Aug 6;62(6):496-504. doi: 10.1016/j.jacc.2013.05.022. Epub 2013 Jun 7.

17.

Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes.

Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC.

Circ Cardiovasc Interv. 2009 Feb;2(1):35-42. doi: 10.1161/CIRCINTERVENTIONS.108.805630. Epub 2009 Feb 10.

18.

Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.

Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ.

JACC Cardiovasc Interv. 2008 Oct;1(5):494-503. doi: 10.1016/j.jcin.2008.06.011.

19.

Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.

Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A.

Circulation. 2007 Jun 26;115(25):3181-8. Epub 2007 Jun 11.

20.

Supplemental Content

Support Center